• Oruka Therapeutics, Inc. recently reported a first-quarter 2026 net loss of US$31.82 million, wider than a year earlier, while releasing encouraging interim psoriasis data showing very high complete skin clearance rates for its lead candidate ORKA-001 and advancing ORKA-002 into Phase 2 trials.
• The company also completed an upsized US$700 million public offering and expanded development plans, underscoring both its capital access and its ambition to build a broader portfolio in immune-mediated skin diseases.
• We will now examine how the positive EVERLAST-A data for ORKA-001 shapes Oruka Therapeutics’ investment narrative despite recent share price weakness.

Find 50 companies with promising cash flow potential yet trading below their fair value.

What Is Oruka Therapeutics' Investment Narrative?

To own Oruka Therapeutics today, you have to believe its IL‑23 and IL‑17 antibody platform can convert strong early psoriasis data into approved products before the cash burn and dilution become too painful. The latest EVERLAST‑A readout and ORKA‑002 Phase 2 start reinforce the core upside catalyst around ORKA‑001’s potential once‑yearly dosing and a broader immune‑mediated skin disease franchise, even as the wider Q1 2026 loss and fresh US$700.35 million equity raise highlight how dependent the story remains on future trial success. Near term, the big swing factors look more concentrated around clinical data quality, regulatory interactions and how the market absorbs the post‑offering share supply, rather than around earnings. The recent news largely sharpens, rather than changes, those priorities.

However, one risk in particular may catch new shareholders off guard. According our valuation report, there's an indication that Oruka Therapeutics' share price might be on the expensive side.

Exploring Other Perspectives

The Simply Wall St Community’s two fair value estimates span roughly US$14 to US$142, underscoring just how far apart individual expectations are. Against that backdrop, concentration of risk in a small, loss making pipeline becomes even more important to weigh.

Explore 2 other fair value estimates on Oruka Therapeutics - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Oruka Therapeutics research is our analysis highlighting 5 important warning signs that could impact your investment decision.
• Our free Oruka Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oruka Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.